Abstract:Recognition that inflammation may represent a common mechanism of disease has been extended to include neuropsychiatric disorders including major depression. Patients with major depression have been found to exhibit increased peripheral blood inflammatory biomarkers, including inflammatory cytokines, which have been shown to access the brain and interact with virtually every pathophysiologic domain known to be involved in depression, including neurotransmitter metabolism, neuroendocrine function, and neural plasticity. Indeed, activation of inflammatory pathways within the brain is believed to contribute to a confluence of decreased neurotrophic support and altered glutamate release/reuptake, as well as oxidative stress, leading to excitotoxicity and loss of glial elements, consistent with neuropathologic findings that characterize depressive disorders. Further instantiating the link between inflammation and depression are data demonstrating that psychosocial stress, a well-known precipitant of mood disorders, is capable of stimulating inflammatory signaling molecules, including nuclear factor kappa B, in part, through activation of sympathetic nervous system outflow pathways. Interestingly, depressed patients with increased inflammatory biomarkers have been found to be more likely to exhibit treatment resistance, and in several studies, antidepressant therapy has been associated with decreased inflammatory responses. Finally, preliminary data from patients with inflammatory disorders, as well as medically healthy depressed patients, suggest that inhibiting proinflammatory cytokines or their signaling pathways may improve depressed mood and increase treatment response to conventional antidepressant medication. Translational implications of these findings include the unique opportunity to identify relevant patient populations, apply immune-targeted therapies, and monitor therapeutic efficacy at the level of the immune system in addition to behavior.

Research progress of microglia and peripheral monocytes in mood disorders

The mediation of immune activation on serotonin and glutamate systems in pathological process of depression

Common Cellular and Molecular Mechanisms and Interactions Between Microglial Activation and Aberrant Neuroplasticity in Depression

Reseach progress in neuroinflammation mechanism in depression.

Noteworthy perspectives on microglia in neuropsychiatric disorders

Microglia in depression: current perspectives

Microglia Sing the Prelude of Neuroinflammation-Associated Depression

Research Progress in Depression and Macrophage Migration Inhibitory Factor

Research Progress on the Role of Microglia Membrane Proteins or Receptors in Neuroinflammation and Degeneration

Inflammatory Signatures of Microglia in Hypercortisolemia-Related Depression

Major Depression Accompanied with Inflammation and Multiple Cytokines Alterations: Evidences from Clinical Patients to Macaca Fascicularis and LPS-induced Depressive Mice Model.

Affective Immunology: The Crosstalk Between Microglia and Astrocytes Plays Key Role?

Microglia in retinal diseases: From pathogenesis towards therapeutic strategies

Inflammatory Signatures of Microglia in the Mouse Model of Corticosterone-Induced Depression

The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes

Research progress of neuroendocrine immune inflammation in depression

Major depressive disorder as a neuro-immune disorder: Origin, mechanisms, and therapeutic opportunities

Neuroinflammation in Alzheimer's disease: insights from peripheral immune cells

Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression

Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression

Depression: Monocytes on my mind